This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martens, T. P. Articles by Oz, M. C. Search for Related Content PubMed PubMed Citation Articles by Martens, T. P. Articles by Oz, M. C. Related Collections Angiogenesis CV surgery: coronary artery disease Coronary circulation

(Circulation. 2006;114:606-614.)
© 2006 American Heart Association, Inc.

New Drugs and Technologies

New Technology for Surgical Coronary Revascularization

Timothy P. Martens, MD; Michael Argenziano, MD; Mehmet C. Oz, MD

From the Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY.

Correspondence to Timothy P. Martens, MD, Division of Cardiothoracic Surgery, 177 Fort Washington Ave, MHB 7-435, New York, NY 10032. E-mail tpm2102@columbia.edu

Key Words: cardiopulmonary bypass • follow-up studies • revascularization • trials

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
In the past decade, the face of surgical coronary revascularization has been changed by a number of advances, most notably the development of minimally invasive techniques, including minimally invasive direct coronary artery bypass (MIDCAB), off-pump coronary artery bypass (OPCAB), and totally endoscopic, robot-assisted coronary artery bypass grafting (TECAB). Initial attempts to perform cardiac operations through small incisions were hindered by the absence of appropriate accessory technology, such as visualization systems, anastomotic devices, stabilizers, and alternative methods of vascular cannulation and cardiopulmonary bypass. With the development of these technologies, surgeons have been increasingly able to perform complex cardiac procedures, including coronary artery bypass grafting (CABG), mitral and aortic valve replacement, and atrial septal defect closure, through smaller-than-traditional incisions. Nonetheless, in many cases, the extent to which incision size has been reduced by these minimally invasive approaches has been matched by a corresponding increase in technical difficulty and operative time—and a potentially decreased safety margin—owing to the constraints imposed by limited or incomplete cardiac exposure.

The emerging field of cell-based therapy represents an attractive alternative to surgical bypass. Spurred on by rapid advances in our understanding of vascular biology and positive results from studies of small- and large-animal models, a number of clinical trials have been conducted exploring the use of multiple cell types, either as sole or adjunctive therapy at the time of open heart surgery. Although significant myogenesis remains elusive, substantial progress with angiogenic cell therapy warrants discussion in the context of surgical revascularization. It is likely that the future . . . [Full Text of this Article]

This article has been cited by other articles:

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				W. J.L. Suyker and C. Borst Coronary Connector Devices: Analysis of 1,469 Anastomoses in 1,216 Patients Ann. Thorac. Surg., May 1, 2008; 85(5): 1828 - 1836. [Abstract] [Full Text] [PDF]